Market research
5JA1.F Sprint Bioscience AB (publ)
F EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 24M
- P/E ratio
- 2.79
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- -0.5
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- SE0006343745
- Market cap
- 24M
- P/E ratio
- 2.79
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- -0.5
About
About Sprint Bioscience AB (publ)
Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of drug candidates to treat cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; DCPS which is in preclinical trial for the treatment of acute myeloid leukemia; VRK1, which is in preclinical development to treat solid tumors; VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; and NNMT for the treatment of solid tumors/chronic kidney diseases. It is also developing STK25, which is in preclinical trial to treat metabolic liver disease that can lead to inflammation and fibrosis; and TREX1, which is in preclinical trial for the treatment of solid tumors and immuno-oncology. The company has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases and evaluation of the STK25 program. The company was incorporated in 2009 and is headquartered in Huddinge, Sweden.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the 5JA1.F discussion.
5 years, 5 months ago
Sprint Bioscience AB (publ) is currently in a long term downtrend where the price is trading 11.7% below its 200 day moving average.
From a valuation standpoint, the stock is 99.7% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 4.2.
Based on the above factors, Sprint Bioscience AB (publ) gets an overall score of 1/5.